Baoying Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2162849/publications.pdf

Version: 2024-02-01

		687363	839539	
17	34,824	13	18	
papers	citations	h-index	g-index	
18	18	18	59389	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine, 2020, 382, 727-733.	27.0	21,542
2	Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, The, 2020, 395, 565-574.	13.7	9,430
3	Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host and Microbe, 2020, 27, 325-328.	11.0	1,860
4	Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science, 2020, 368, 1016-1020.	12.6	1,537
5	Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Nature Communications, 2019, 10, 3068.	12.8	122
6	Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient. Journal of Infectious Diseases, 2018, 218, 1249-1260.	4.0	63
7	Comparative Transcriptome Analysis Reveals the Intensive Early Stage Responses of Host Cells to SARS-CoV-2 Infection. Frontiers in Microbiology, 2020, 11, 593857.	3 . 5	62
8	Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerging Microbes and Infections, 2018, 7, 1-10.	6.5	43
9	A novel neutralizing monoclonal antibody targeting the N-terminal domain of the MERS-CoV spike protein. Emerging Microbes and Infections, 2017, 6, 1-7.	6.5	37
10	Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus. Virologica Sinica, 2018, 33, 453-455.	3.0	17
11	DNA Vaccines Expressing the Envelope and Membrane Proteins Provide Partial Protection Against SARS-CoV-2 in Mice. Frontiers in Immunology, 2022, 13, 827605.	4.8	17
12	Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates. Vaccine, 2019, 37, 2122-2130.	3.8	16
13	Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice. Frontiers in Immunology, 2021, 12, 655743.	4.8	9
14	The immune response of rhesus macaques to novel vaccines comprising hepatitis B virus S, PreS1, and Core antigens. Vaccine, 2018, 36, 3740-3746.	3.8	8
15	Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants. Vaccines, 2022, 10, 956.	4.4	8
16	NS1-based DNA vaccination confers mouse protective immunity against ZIKV challenge. Infection, Genetics and Evolution, 2020, 85, 104521.	2.3	7
17	Dr. Chi-Ming Chu: Respected founder of molecular virology and pioneer of biologicals in China. Protein and Cell, 2017, 8, 629-633.	11.0	1